Skip to main content
NewslettersWatchlist

Sanofi-Aventis S.A. ADR(SNY-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low47.56
Day High48.04
Open:47.64
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
the globe and mail

New multiple sclerosis drug by Sanofi delays progressive form of disease by 31 per cent in trial

Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end of MS pill Aubagio’s patent protection
PR Newswire
Beyfortus® immunization to protect infants from RSV has begun
Motley Fool
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
Motley Fool
Why Sanofi Stock Flew Higher on Friday
Motley Fool
Sanofi (SNY) Q3 2024 Earnings Call Transcript
Motley Fool
This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip?
Baystreet
Bank Rate Decision Due Next Week
Barchart
This Biotech Stock Insider is Buying Shares, Should You?
Motley Fool
2 Artificial Intelligence Stocks That Could Deliver Explosive Gains
Barchart
1 AI Biotech Stock That Just Scored a Major Milestone
MarketBeat
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Newswire.ca
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies
Reuters
New multiple sclerosis drug by Sanofi delays progressive form of disease by 31 per cent in trial
Motley Fool
Should You Buy Novavax Stock After This Regulatory Win?
Barchart
You Can Stop Looking, Here's the Perfect Stock for the Current Market
Motley Fool
Why Sanofi Stock Was Robustly Healthy Today
Motley Fool
Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy?
Investor Brand Network
Annovis Bio (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
GlobeNewswire
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
Motley Fool
Where Will Novavax Be in 5 Years?
Motley Fool
Sanofi (SNY) Q2 2024 Earnings Call Transcript
Motley Fool
25 Best Artificial Intelligence Stocks to Buy Right Now
Motley Fool
Where Will Novavax Be in 1 Year?

Profile

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.